News · Latest research
The MS research world moves fast and shouts loudly. We read widely, pick what genuinely matters, and hand it to you with sources attached — so you can go as deep as you like.
Hand-curated · updated July 2026 · every card links to its original source
Researchers at San Raffaele in Milan found that bavisant — a molecule originally studied for sleep-wake disorders — protected nerve fibres and promoted remyelination in experimental MS models. Early days, but it targets the two mechanisms that matter most in progression.
By combining MRI scans with blood biomarkers, researchers have identified subtypes of MS that differ in when and how severely neurodegeneration unfolds — a step toward genuinely personalised treatment decisions rather than one-size-fits-all.
Melbourne's own WEHI can now examine more than one hundred genetic risk factors for MS at once — bringing science closer to understanding how the disease actually develops, and where it might be interrupted.
A strong body of evidence now points to Epstein-Barr virus as the trigger of MS. A wave of vaccine trials is underway aiming at that root cause — the kind of research that could one day change the story for the next generation.
Cambridge's CCMR Two trial is testing whether two well-known, inexpensive drugs — metformin and clemastine — can work together to stimulate remyelination in people with relapsing-remitting MS already on treatment.
Over three years, the investigational therapy frexalimab cut blood neurofilament light (a marker of nerve damage) by 47% and CXCL13 by 48% — encouraging signs for a new, non-depleting way of calming the immune system.